Advances and challenges in targeting FGFR signalling in cancer

Nature Reviews Cancer

Volumn 17, Issue 5, 2017, Pages 318-332

  Babina, Irina S ^a   Turner, Nicholas C ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SELECTIVE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE MUTATION; HOSPITAL; HUMAN; MALIGNANT NEOPLASM; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; FIBROBLAST GROWTH FACTORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 85015654600     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2017.8     Document Type: Review

References (183)

1. Sleeman, M., et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 271, 171-182 (2001).
2. Itoh, N., Ornitz, D. M. Fibroblast growth factors: From molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121-130 (2011).
3. Dienstmann, R., et al. Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors. Ann. Oncol. 25, 552-563 (2014).
4. Dieci, M. V., Arnedos, M., Andre, F., Soria, J. C. Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives. Cancer Discov. 3, 264-279 (2013).
5. Smyth, E. C., et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. J. Clin. Oncol. 33 (Suppl.), abstr. 2508 (2015).
6. Tabernero, J., et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 33, 3401-3408 (2015).
7. Andre, F., et al. Targeting FGFR with dovitinib (TKI258): Preclinical and clinical data in breast cancer. Clin. Cancer Res. 19, 3693-3702 (2013).
8. Konecny, G. E., et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 16, 686-694 (2015).
9. Yang, W., et al. Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: A meta-analysis. J. Thorac. Dis. 6, 803-809 (2014).
10. Weiss, J., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl Med. 2, 62ra93 (2010).
11. Peifer, M., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104-1110 (2012).
12. Cihoric, N., et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br. J. Cancer 110, 2914-2922 (2014).
13. Reis-Filho, J. S., et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12, 6652-6662 (2006).
14. Courjal, F., et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups. Cancer Res. 57, 4360-4367 (1997).
15. Lee, H. J., et al. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann. Surg. Oncol. 21, 1561-1568 (2014).
16. Singleton, K. R., et al. Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC. Cancer Res. 75, 4398-4406 (2015).
17. Turner, N., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085-2094 (2010).
18. Mohammadi, M., et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904 (1998).
19. Dutt, A., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl Acad. Sci. USA 105, 8713-8717 (2008).
20. Campbell, J., et al. Large-scale profiling of kinase dependencies in cancer cell lines. Cell Rep. 14, 2490-2501 (2016).
21. Guagnano, V., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2, 1118-1133 (2012).
22. Matsumoto, K., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br. J. Cancer 106, 727-732 (2012).
23. Turner, N., et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29, 2013-2023 (2010).
24. Ueda, T., et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res. 59, 6080-6086 (1999).
25. Pearson, A., et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6, 838-851 (2016).
26. Verstraete, M., et al. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC Cancer 15, 946 (2015).
27. Reynisdottir, I., et al. High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. Cancer Med. 2, 437-446 (2013).
28. Baykara, O., Bakir, B., Buyru, N., Kaynak, K., Dalay, N. Amplification of chromosome 8 genes in lung cancer. J. Cancer 6, 270-275 (2015).
29. Zhang, X., et al. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. PLoS ONE 8, e72053 (2013).
30. Fischbach, A., et al. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology 66, 639-649 (2015).
31. Tomlinson, D. C., Baldo, O., Harnden, P., Knowles, M. A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213, 91-98 (2007).
32. Helsten, T., et al. The FGFR landscape in cancer: Analysis of 4, 853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259-267 (2015).
33. Greenman, C., et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
34. Gao, J., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
35. Ibrahimi, O. A., et al. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum. Mol. Genet. 13, 2313-2324 (2004).
36. Ibrahimi, O. A., et al. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc. Natl Acad. Sci. USA 98, 7182-7187 (2001).
37. Wilkie, A. O., Patey, S. J., Kan, S. H., van den Ouweland, A. M., Hamel, B. C. FGFs, their receptors, human limb malformations: Clinical and molecular correlations. Am. J. Med. Genet. 112, 266-278 (2002).
38. Tanizaki, J., et al. Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2. Cancer Res. 75, 3139-3146 (2015).
39. Cappellen, D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20 (1999).
40. Rosty, C., et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol. Cancer 4, 15 (2005).
41. Bernard-Pierrot, I., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27, 740-747 (2006).
42. Chen, H., et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717-730 (2007).
43. Hart, K. C., et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, FGFR4. Oncogene 19, 3309-3320 (2000).
44. Taylor, J. G. VI, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 119, 3395-3407 (2009).
45. Andersen, S. W., et al. Breast cancer susceptibility associated with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy use in a population-based United States study. Menopause 20, 354-358 (2013).
46. Hunter, D. J., et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870-874 (2007).
47. Meyer, K. B., et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6, e108 (2008).
48. Frullanti, E., et al. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur. J. Cancer Prev. 20, 340-347 (2011).
49. Bange, J., et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 62, 840-847 (2002).
50. Ulaganathan, V. K., Sperl, B., Rapp, U. R., Ullrich, A. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. Nature 528, 570-574 (2015).
51. Singh, D., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231-1235 (2012).
52. Wu, Y. M., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636-647 (2013).
53. Ha, G. H., Kim, J. L., Breuer, E. K. Transforming acidic coiled-coil proteins (TACCs) in human cancer. Cancer Lett. 336, 24-33 (2013).
54. Hood, F. E., Royle, S. J. Pulling it together: The mitotic function of TACC3. Bioarchitecture 1, 105-109 (2011).
55. Williams, S. V., Hurst, C. D., Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795-803 (2013).
56. Sia, D., et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun. 6, 6087 (2015).
57. Arai, Y., et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59, 1427-1434 (2014).
58. Giacomini, A., et al. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget 6, 13790-13802 (2015).
59. Wan, X., et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl Med. 6, 252ra122 (2014).
60. Tanner, Y., Grose, R. P. Dysregulated FGF signalling in neoplastic disorders. Semin. Cell Dev. Biol. 53, 126-135 (2015).
61. Tuomela, J., Harkonen, P. Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression. Reprod. Biol. 14, 16-24 (2014).
62. Feng, S., Dakhova, O., Creighton, C. J., Ittmann, M. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 73, 2551-2562 (2013).
63. Nagamatsu, H., et al. FGF19 promotes progression of prostate cancer. Prostate 75, 1092-1101 (2015).
64. Feng, S., Wang, J., Zhang, Y., Creighton, C. J., Ittmann, M. FGF23 promotes prostate cancer progression. Oncotarget 6, 17291-17301 (2015).
65. Lee, E. K., et al. FGF23: Mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia? Med. Hypotheses 83, 482-487 (2014).
66. Schuuring, E. The involvement of the chromosome 11q13 region in human malignancies: Cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 159, 83-96 (1995).
67. Karlsson, E., et al. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 50, 775-787 (2011).
68. Ormandy, C. J., Musgrove, E. A., Hui, R., Daly, R. J., Sutherland, R. L. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 78, 323-335 (2003).
69. Sawey, E. T., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347-358 (2011).
70. Nicholes, K., et al. A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 160, 2295-2307 (2002).
71. Zhou, M., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 74, 3306-3316 (2014).
72. Wu, A. L., et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 6, e17868 (2011).
73. Chen, J., et al. TGF-beta1 and FGF2 stimulate the epithelial-mesenchymal transition of HERS cells through a MEK-dependent mechanism. J. Cell. Physiol. 229, 1647-1659 (2014).
74. Shirakihara, T., et al. TGF-beta regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 30, 783-795 (2011).
75. Fillmore, C. M., et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc. Natl Acad. Sci. USA 107, 21737-21742 (2010).
76. Acevedo, V. D., et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12, 559-571 (2007).
77. Marek, L., et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 75, 1 96-207 (2009).
78. Sharpe, R., et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin. Cancer Res. 17, 5275-5286 (2011).
79. Abramson, V. G., Lehmann, B. D., Ballinger, T. J., Pietenpol, J. A. Subtyping of triple-negative breast cancer: Implications for therapy. Cancer 121, 8-16 (2015).
80. Ruotsalainen, T., Joensuu, H., Mattson, K., Salven, P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 11, 1492-1495 (2002).
81. Nguyen, M., et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl Cancer Inst. 86, 356-361 (1994).
82. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., McKeehan, W. L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell. Biol. 13, 4513-4522 (1993).
83. Ranieri, D., Belleudi, F., Magenta, A., Torrisi, M. R. HPV16 E5 expression induces switching from FGFR2b to FGFR2c and epithelial-mesenchymal transition. Int. J. Cancer 137, 61-72 (2015).
84. Chaffer, C. L., et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Res. 66, 11271-11278 (2006).
85. Ishiwata, T., et al. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation. Am. J. Pathol. 180, 1928-1941 (2012).
86. Matsuda, Y., Hagio, M., Seya, T., Ishiwata, T. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells. Mol. Cancer Ther. 11, 2010-2020 (2012).
87. Broadley, K. N., et al. Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab. Invest. 61, 571-575 (1989).
88. Ortega, S., Ittmann, M., Tsang, S. H., Ehrlich, M., Basilico, C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor. Proc. Natl Acad. Sci. USA 95, 5672-5677 (1998).
89. Compagni, A., Wilgenbus, P., Impagnatiello, M. A., Cotten, M., Christofori, G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60, 7163-7169 (2000).
90. Ronca, R., Giacomini, A., Rusnati, M., Presta, M. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin. Ther. Targets 19, 1361-1377 (2015).
91. Pepper, M. S., Mandriota, S. J., Jeltsch, M., Kumar, V., Alitalo, K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell. Physiol. 177, 439-452 (1998).
92. Yan, W., Bentley, B., Shao, R. Distinct angiogenic mediators are required for basic fibroblast growth factor-A nd vascular endothelial growth factor-induced angiogenesis: The role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol. Biol. Cell 19, 2278-2288 (2008).
93. Kopetz, S., et al. Phase II trial of infusional fluorouracil, irinotecan, bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28, 453-459 (2010).
94. Allen, E., Walters, I. B., Hanahan, D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin. Cancer Res. 17, 5299-5310 (2011).
95. Zhang, K., et al. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res. 73, 1298-1307 (2013).
96. Luo, L. Y., et al. The tyrosine kinase adaptor protein FRS2 is oncogenic and amplified in high-grade serous ovarian cancer. Mol. Cancer Res. 13, 502-509 (2015).
97. Timsah, Z., et al. Competition between Grb2 and Plcgamma1 for FGFR2 regulates basal phospholipase activity and invasion. Nat. Struct. Mol. Biol. 21, 180-188 (2014).
98. Timsah, Z., et al. Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. Oncogene 35, 2186-2196 (2016).
99. Timsah, Z., et al. Expression pattern of FGFR2, Grb2 and Plcgamma1 acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. Am. J. Cancer Res. 5, 3135-3148 (2015).
100. Angevin, E., et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin. Cancer Res. 19, 1257-1268 (2013).
101. Motzer, R. J., et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial. Lancet Oncol. 15, 286-296 (2014).
102. Soria, J. C., et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics of lucitanib in advanced solid tumors. Ann. Oncol. 25, 2244-2251 (2014).
103. Okamoto, I., et al. Phase I safety, pharmacokinetic, biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol. Cancer Ther. 9, 2825-2833 (2010).
104. Cortes, J. E., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 369, 1783-1796 (2013).
105. Johnson, D. E., Williams, L. T. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60, 1-41 (1993).
106. Lesca, E., Lammens, A., Huber, R., Augustin, M. Structural analysis of the human fibroblast growth factor receptor 4 kinase. J. Mol. Biol. 426, 3744-3756 (2014).
107. Andre, F., et al. Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Cancer Res. 73 (Suppl.), abstr. LB-145 (2013).
108. Nogova, L., et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase I, dose-escalation and dose-expansion study. J. Clin. Oncol. 35, 157-165 (2017).
109. Bang, Y.-J., et al. A randomized, open-label phase II study of AZD4547 (AZD) versus paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study. J. Clin. Oncol. 33 (Suppl.), abstr. 4014 (2015).
110. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02150967 (2016).
111. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02257541 (2016).
112. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02160041 (2016).
113. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02365597 (2017).
114. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01212107 (2015).
115. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01363024 (2016).
116. ODonnell, P., et al. A phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients (pts) with advanced solid tumors. Eur. J. Cancer 48, 191-192 (2012).
117. Sun, H. D., et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am. J. Physiol. 292, E964-E976 (2007).
118. Gemo, A. T., et al. FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification. Cancer Res. 74 (Suppl.), abstr. 5446 (2014).
119. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02318329 (2017).
120. Bendell, J. C., et al. FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors. J. Clin. Oncol. 34 (Suppl. 4S), 140 (2016).
121. Harding, T. C., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl Med. 5, 178ra39 (2013).
122. Tolcher, A. W., et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann. Oncol. 27, 526-532 (2016).
123. Andre, F., Delaloge, S., Soria, J. C. Biology-driven phase II trials: What is the optimal model for molecular selection? J. Clin. Oncol. 29, 1236-1238 (2011).
124. Malchers, F., et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 4, 246-257 (2014).
125. Wynes, M. W., et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin. Cancer Res. 20, 3299-3309 (2014).
126. Kotani, H., et al. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene 35, 3587-3597 (2015).
127. Kimelman, D., Kirschner, M. Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell 51, 869-877 (1987).
128. Brewer, J. R., Mazot, P., Soriano, P. Genetic insights into the mechanisms of Fgf signaling. Genes Dev. 30, 751-771 (2016).
129. Corson, L. B., Yamanaka, Y., Lai, K. M., Rossant, J. Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development 130, 4527-4537 (2003).
130. Shiang, C. Y., et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res. Treat. 123, 747-755 (2010).
131. Xian, W., Schwertfeger, K. L., Vargo-Gogola, T., Rosen, J. M. Pleiotropic effects of FGFR1 on cell proliferation, survival, migration in a 3D mammary epithelial cell model. J. Cell Biol. 171, 663-673 (2005).
132. Welm, B. E., et al. Inducible dimerization of FGFR1: Development of a mouse model to analyze progressive transformation of the mammary gland. J. Cell Biol. 157, 703-714 (2002).
133. French, D. M., et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE 7, e36713 (2012).
134. Hagel, M., et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 5, 424-437 (2015).
135. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02421185 (2017).
136. Liao, R. G., et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73, 5195-5205 (2013).
137. Gozgit, J. M., et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother. Pharmacol. 71, 1315-1323 (2013).
138. Scheller, T., et al. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br. J. Cancer 112, 841-850 (2015).
139. Gavine, P. R., et al. AZD4547: An orally bioavailable, potent, selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045-2056 (2012).
140. Zhao, G., et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther. 10, 2200-2210 (2011).
141. Ronca, R., et al. Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell 28, 225-239 (2015).
142. Blencke, S., et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691-701 (2004).
143. Byron, S. A., et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, ponatinib ATP-competitive inhibitors. Neoplasia 15, 975-988 (2013).
144. Chell, V., et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 32, 3059-3070 (2013).
145. Goyal, L., et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-16-1000 (2016).
146. Tan, L., et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc. Natl Acad. Sci. USA 111, E4869-E4877 (2014).
147. Wang, J., et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene 34, 2167-2177 (2015).
148. Herrera-Abreu, M. T., et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 3, 1058-1071 (2013).
149. Hughes, S. E. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem. 45, 1005-1019 (1997).
150. Zhang, X., Bao, L., Yang, L., Wu, Q., Li, S. Roles of intracellular fibroblast growth factors in neural development and functions. Sci. China Life Sci. 55, 1038-1044 (2012).
151. Beenken, A., Mohammadi, M. The FGF family: Biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8, 235-253 (2009).
152. Fernandes-Freitas, I., Owen, B. M. Metabolic roles of endocrine fibroblast growth factors. Curr. Opin. Pharmacol. 25, 30-35 (2015).
153. Degirolamo, C., Sabba, C., Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51-69 (2015).
154. Gotoh, N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 99, 1319-1325 (2008).
155. Fearon, A. E., Grose, R. P. Grb-ing receptor activation by the tail. Nat. Struct. Mol. Biol. 21, 113-114 (2014).
156. Wong, A., Lamothe, B., Lee, A., Schlessinger, J., Lax, I. FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc. Natl Acad. Sci. USA 99, 6684-6689 (2002).
157. Fong, C. W., et al. Tyrosine phosphorylation of Sprouty2 enhances its interaction with c-Cbl and is crucial for its function. J. Biol. Chem. 278, 33456-33464 (2003).
158. Sieglitz, F., et al. Antagonistic feedback loops involving Rau and Sprouty in the Drosophila eye control neuronal and glial differentiation. Sci. Signal. 6, ra96 (2013).
159. Formisano, L., et al. FGFR1 is associated with resistance to interaction with estrogen receptor (ER) ? endocrine therapy in ER+/FGFR1-amplified breast cancer. Cancer Res. 75 (Suppl.), abstr. 2435 (2015).
160. Fernanda Amary, M., et al. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer Med. 3, 980-987 (2014).
161. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01202591 (2016).
162. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01791985 (2015).
163. Manchado, E., et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534, 647-651 (2016).
164. Ware, K. E., et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 5, e14117 (2010).
165. Yadav, V., et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J. Biol. Chem. 287, 28087-28098 (2012).
166. Kim, B., et al. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34, 1083-1093 (2015).
167. Garcia-Murillas, I., et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl Med. 7, 302ra133 (2015).
168. Yu, M., et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216-220 (2014).
169. Crystal, A. S., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
170. Terai, H., et al. Activation of the FGF2-FGFR1 autocrine pathway: A novel mechanism of acquired resistance to gefitinib in NSCLC. Mol. Cancer Res. 11, 759-767 (2013).
171. Ware, K. E., et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2, e39 (2013).
172. Azuma, K., et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget 5, 5908-5919 (2014).
173. Pietras, K., Pahler, J., Bergers, G., Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5, e19 (2008).
174. Javidi-Sharifi, N., et al. Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Res. 75, 880-891 (2015).
175. Forbes, S. A., et al. COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015).
176. Shihab, H. A., et al. Predicting the functional, molecular, phenotypic consequences of amino acid substitutions using hidden Markov models. Hum. Mutat. 34, 57-65 (2013).
177. Trudel, S., et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105, 2941-2948 (2005).
178. O'Hare, T., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009).
179. Bello, E., et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 71, 1396-1405 (2011).
180. Guagnano, V., et al. Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 54, 7066-7083 (2011).
181. Angibaud, P. R., et al. Discovery of JNJ-42756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment based approach. Cancer Res. 74 (Suppl.), abstr. 4748 (2014).
182. Ochiiwa, H., et al. TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Mol. Cancer Ther. 12 (11 Suppl.), abstr. A270 (2013).
183. Nakanishi, Y., et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol. Cancer Ther. 13, 2547-2558 (2014).